Suppr超能文献

国际卫生技术评估网络(INAHTA)成员机构关于引人入胜、适应性强且具影响力的卫生技术评估的故事。

INAHTA member agency stories of engaging, adaptable, and impactful HTA.

作者信息

Söderholm Werkö Sophie, Bouchard Sylvie, Romli Erni Z, Li Chunmei, Huang Li-Ying, Pelekanou Charlotte, Elston Lauren, Schuller Tara

机构信息

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.

Institut national d'excellence en santé et en services sociaux, Québec, QC, Canada.

出版信息

Int J Technol Assess Health Care. 2024 Dec 10;41(1):e4. doi: 10.1017/S0266462324004732.

Abstract

Health technology assessment (HTA) agencies assess evidence to support decision making about which technologies to provide and pay for in the health system. HTA impact is understood as the influence that HTA report findings can have in the health system, including impacts on reimbursement decisions, changes to health outcomes, or broader system or societal impacts. The International Network of Agencies for Health Technology Assessment (INAHTA) is a global network of publicly funded HTA agencies. INAHTA's mission, in part, is to advance the impact of HTA to support reimbursement decisions and the optimal use of health system resources. Each year, INAHTA awards the David Hailey Award for Best Impact Story to the member agency that shares the best story, as voted by fellow members, about HTA impact. The impact story sharing program in INAHTA contributes to a deeper understanding of what works well (or not so well) in achieving HTA impact. This paper provides six impact stories from agencies that were finalists for the 2021 and 2022 David Hailey Impact Award for Best Impact Story: the Institut national d'excellence en santé et en services sociaux, the Malaysian Health Technology Assessment Section, Ontario Health, the Center for Drug Evaluation, the National Institute for Health and Care Excellence, and Health Technology Wales. These stories demonstrate that HTA agencies can, in differing ways, effectively support governments in their efforts to place evidence at the centre of decision making.

摘要

卫生技术评估(HTA)机构评估相关证据,以支持关于在卫生系统中提供哪些技术并为之付费的决策。HTA的影响被理解为HTA报告结果在卫生系统中可能产生的影响,包括对报销决策的影响、健康结果的变化,或更广泛的系统或社会影响。国际卫生技术评估机构网络(INAHTA)是一个由公共资助的HTA机构组成的全球网络。INAHTA的部分使命是提升HTA的影响力,以支持报销决策和卫生系统资源的优化利用。每年,INAHTA都会将最佳影响故事大卫·黑利奖授予分享最佳故事的成员机构,该故事由成员投票选出,内容是关于HTA的影响。INAHTA的影响故事分享计划有助于更深入地了解在实现HTA影响方面哪些做法有效(或不太有效)。本文提供了来自六家机构的影响故事,这些机构是2021年和2022年大卫·黑利最佳影响故事奖的入围者:魁北克国家公共卫生与社会服务卓越研究所、马来西亚卫生技术评估部门、安大略省卫生厅、药品评价中心、英国国家卫生与临床优化研究所和威尔士卫生技术评估机构。这些故事表明,HTA机构可以通过不同方式,有效地支持政府将证据置于决策核心的努力。

相似文献

1
INAHTA member agency stories of engaging, adaptable, and impactful HTA.
Int J Technol Assess Health Care. 2024 Dec 10;41(1):e4. doi: 10.1017/S0266462324004732.
2
INSIGHTS FROM THE FRONT LINES: A COLLECTION OF STORIES OF HTA IMPACT FROM INAHTA MEMBER AGENCIES.
Int J Technol Assess Health Care. 2017 Jan;33(4):409-410. doi: 10.1017/S0266462317001076.
3
Demonstrating the influence of HTA: INAHTA member stories of HTA impact.
Int J Technol Assess Health Care. 2020 Nov 5;37:e8. doi: 10.1017/S0266462320000835.
4
The 'Top 10' Challenges for Health Technology Assessment: INAHTA Viewpoint.
Int J Technol Assess Health Care. 2020;36(1):1-4. doi: 10.1017/S0266462319000825. Epub 2019 Nov 28.
5
Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe.
Int J Health Policy Manag. 2020 Jan 1;9(1):27-33. doi: 10.15171/ijhpm.2019.72.
6
HTA responsiveness to today's challenges to health systems: a responsible innovation in health perspective.
Int J Technol Assess Health Care. 2025 Mar 3;41(1):e16. doi: 10.1017/S0266462325000121.
7
Oncology drug health technology assessment recommendations: Canadian versus UK experiences.
Clinicoecon Outcomes Res. 2014 Jul 16;6:357-67. doi: 10.2147/CEOR.S66309. eCollection 2014.
9
Development of the International Network of Agencies for Health Technology Assessment.
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:24-7. doi: 10.1017/S0266462309090370. Epub 2009 Jun 8.

本文引用的文献

1
UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update.
Appl Health Econ Health Policy. 2022 Sep;20(5):669-680. doi: 10.1007/s40258-022-00735-y. Epub 2022 Jul 18.
2
Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System.
Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6548-6556. doi: 10.26355/eurrev_202111_27097.
4
Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan.
Int J Technol Assess Health Care. 2020 Dec 21;37:e26. doi: 10.1017/S0266462320002160.
5
Demonstrating the influence of HTA: INAHTA member stories of HTA impact.
Int J Technol Assess Health Care. 2020 Nov 5;37:e8. doi: 10.1017/S0266462320000835.
7
The 'Top 10' Challenges for Health Technology Assessment: INAHTA Viewpoint.
Int J Technol Assess Health Care. 2020;36(1):1-4. doi: 10.1017/S0266462319000825. Epub 2019 Nov 28.
8
The burden of rare diseases.
Am J Med Genet A. 2019 Jun;179(6):885-892. doi: 10.1002/ajmg.a.61124. Epub 2019 Mar 18.
9
Outcomes and Impacts of 10-Year HTA Implementation in Taiwan.
Int J Technol Assess Health Care. 2019;35(6):441-445. doi: 10.1017/S0266462319000011. Epub 2019 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验